Document Detail

A postmarketing surveillance study of dexrabeprazole in the treatment of acid peptic disorders.
MedLine Citation:
PMID:  19585824     Owner:  NLM     Status:  MEDLINE    
Dexrabeprazole [R(+) rabeprazole] is a novel proton-pump inhibitor which has recently become available in India for the treatment of acid peptic diseases. Experimental and clinical studies have shown superiority of dexrabeprazole (at half the recommended rabeprazole dose) over rabeprazole in terms of favourable pharmacokinetics, better efficacy and faster and greater healing activity. Results of present study in a large population of 4931 patients of acid peptic disorders, reconfirmed safety and efficacy of dexrabeprazole 10 mg once daily in the treatment of gastro-oesophageal reflux disease and also showed its effectiveness in the treatment of patients with peptic ulcers (gastric/duodenal).
S C Jain;
Related Documents :
7068924 - Luminal ions and short chain fatty acids as markers of functional activity of the mucos...
6439224 - Evaluation of a new antacid, almagate.
11860414 - Minor effects of helicobacter pylori on gastric secretion and dose of lansoprazole duri...
2563344 - Experience with topical administration of 4-aminosalicylic acid in ulcerative colitis.
6953234 - Modification of a simple method for determination of gamma-2 phase of dental amalgam.
15767324 - Storage oil breakdown during embryo development of brassica napus (l.).
Publication Detail:
Type:  Clinical Trial, Phase IV; Journal Article    
Journal Detail:
Title:  Journal of the Indian Medical Association     Volume:  107     ISSN:  0019-5847     ISO Abbreviation:  J Indian Med Assoc     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-07-09     Completed Date:  2009-08-20     Revised Date:  2013-04-16    
Medline Journal Info:
Nlm Unique ID:  7505608     Medline TA:  J Indian Med Assoc     Country:  India    
Other Details:
Languages:  eng     Pagination:  111-3     Citation Subset:  IM    
Digestive Endoscopy Clinic and A Day Care Center, Pune 411011.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
2-Pyridinylmethylsulfinylbenzimidazoles / adverse effects,  therapeutic use*
Anti-Ulcer Agents / adverse effects,  therapeutic use*
Gastroesophageal Reflux / drug therapy*
Middle Aged
Peptic Ulcer / drug therapy*
Product Surveillance, Postmarketing
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 32828355LL/rabeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ewing's sarcoma/ primitive neuro-ectoclermal tumour: a case report.
Next Document:  Compiled report on clinical efficacy and safety of nifedipine retard 10/20/nifedipine CD 30, as a fi...